Fleury, one of Brazils leading diagnostic medicine groups, has agreed to purchase Hemolab Medicina Laboratorial for R$39.5 ($7) million, according to an official company statement.Hemolab operates 15 clinical analysis and pathology units across nine cities in Minas Gerais.
Last year, Hemolab reported R$31 million in revenue, reflecting its established presence in the region.This acquisition marks another step in Fleurys strategy to expand its footprint through targeted purchases.
The company has pursued similar moves in recent years, including the acquisition of Mthodos in southern Minas Gerais.It also combined with Hermes Pardini, adding more than 500 service units and raising Fleurys combined annual revenue to R$7.1 billion.
The group now operates 108 units in Minas Gerais alone.Fleury paid a multiple of 4.7 times Hemolabs earnings before interest, taxes, depreciation, and amortization (EBITDA), dropping to 3.4 times when considering expected synergies.Fleury Expands Regional Reach with R$39.5 Million Hemolab Acquisition.
(Photo Internet reproduction)These figures show that Fleury expects to improve efficiency and profitability by integrating Hemolabs operations.
The companys CEO, Jeane Tsutsui, stated that the acquisition aligns with Fleurys financial strength and strategic criteria, including price, cultural fit, and growth potential.Fleurys expansion reflects a broader trend in Brazils healthcare sector, where large groups consolidate smaller regional players to gain scale and efficiency.
This approach allows companies to lower costs, improve service quality, and expand their customer base.In the case of Fleury, the companys recent acquisitions have focused on regions with growing demand for diagnostics and a high proportion of residents with health insurance.Hemolab, with over 30 years of experience, brings local expertise and a reputation for quality service.
Fleurys integration of Hemolab could mean broader access to advanced diagnostics for patients in Minas Gerais.
The deal remains subject to regulatory approval.Fleurys acquisition strategy has not increased its debt levels, as the company maintains a leverage rate of about 1.2 times net debt.
The group continues to invest in technology and organic growth, aiming to strengthen its position as a leading healthcare provider in Brazils competitive diagnostics market.